Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Interferon alpha-2a in cutaneous T-cell lymphoma.

M L Vegna¹, G Papa, D Defazio

¹Dipartimento di Biopatologia, Umana, Università La Sapienza, Rome, Italy.

European Journal of Haematology. Supplementum

|January 1, 1990

Summary

Interferon alpha-2a shows high efficacy in treating cutaneous T-cell lymphoma, with a 74% response rate. This treatment is well-tolerated and offers durable remissions for many patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?

British journal of haematology·2001

Same author

Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001

Same author

Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.

Annals of oncology : official journal of the European Society for Medical Oncology·2001

Same author

Granulocytic sarcoma with breast and skin presentation: a report of a case successfully treated by local radiation and systemic chemotherapy.

Acta haematologica·2000

Same author

High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study.

Bone marrow transplantation·2000

Same author

Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto.

British journal of haematology·2000

Area of Science:

Oncology
Dermatology
Immunology

Background:

Cutaneous T-cell lymphoma (CTCL) is a group of malignant diseases.
Effective and well-tolerated treatments for untreated CTCL are needed.

Purpose of the Study:

To evaluate the therapeutic efficacy and toxicity of subcutaneous interferon alpha-2a in newly diagnosed CTCL patients.

Main Methods:

23 CTCL patients received daily interferon alpha-2a (IFN) with dose escalation (3-18 million units) for 12 weeks.
Patients achieving complete (CR) or partial remission (PR) received maintenance IFN (3x weekly for 6-9 months).

Main Results:

An objective tumor response was observed in 17 patients (74%), with 8 (35%) achieving CR and 9 (39%) achieving PR.

Related Experiment Videos

Disease stage predicted response to IFN therapy. Treatment was generally well-tolerated, with manageable liver toxicity and leukopenia.

Long-term remissions were observed in CR patients, while PR patients showed variable response durations.

Conclusions:

Interferon alpha-2a is a highly effective treatment for untreated CTCL, demonstrating a 74% overall response rate.
The observed toxicity profile was acceptable, and the treatment led to durable responses in a significant proportion of patients.